Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of SOM230 LAR in Combination With Bortezomib and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

NCT01329289 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT01329289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01329289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of SOM230 LAR in Combination With Bortezomib and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Lead sponsor
University of Pittsburgh
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2011
Completion date
February 29, 2012
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, multiple myeloma in relapse